Understanding GLP-1-Related Facial Volume Loss: Why Timing Matters When you lose weight rapidly with GLP-1 medications, your face doesnt just get slimmer it loses volume in specific ways that can dramatically age your appearance
"Additional insights from Europe allow us to refine our approach, meeting local needs while staying ahead of the curve in this rapidly evolving space." "With our strong network and understanding of the evolving GLP-1 space, we are committed to delivering innovative solutions that meet the emerging demands of the European market," said Anna Maria Marra, CEO Europe, Havas Health Network
10.1016/j.expneurol.2009.09.030 17 ChenY.YangC.WangZ
The FDA prescribing information for Mounjaro and Zepbound does not highlight arthralgia as a common adverse reaction, and joint inflammation is not identified as a known pharmacologic effect of GIP or GLP-1 receptor activation
10.1097/PSY.0000000000000537 Pubmed Abstract CrossRef Google Scholar View reference in article 82
Within a year of approval, the FDA began receiving reports of adverse health events from patients using the drug
